X

Trial Profile

A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nevanimibe (Primary)
Indications Congenital adrenal hyperplasia
Focus Proof of concept; Therapeutic Use
Sponsors Millendo Therapeutics

Most Recent Events

10 Aug 2020 Early results assessing tolerability and short-term safety published in the Journal of Clinical Endocrinology and Metabolism
26 Jun 2020 Results published in the Journal of Clinical Endocrinology and Metabolism
20 Mar 2018 Results (n=10) assessing the safety and efficacy of ATR-101 in patients with congenital adrenal hyperplasia, were presented at The 100th Annual Meeting of the Endocrine Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com